Clinical Trial Update: Pembrolizumab + MRGOO3 as Neoadjuvant in NPC [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of pembrolizumab in combination with MRGOO3 for locoregionally advanced nasopharyngeal carcinoma is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• MRGOO3 (MRGOO3)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: NPC, Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING